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Poor data have been previously reported about the mutation rates in K-RAS, BRAF, and PIK3CA genes among patients with
hepatocellular carcinoma (HCC). Here we further elucidated the role of these genes in pathogenesis of primary hepatic
malignancies. Archival tumour tissue from 65 HCC patients originating from South Italy were screened for mutations in
these candidate genes by direct sequencing. Overall, oncogenic mutations were detected in 15 (23%) patients for BRAF gene,
18 (28%) for PIK3CA gene, and 1 (2%) for K-RAS gene. Using statistical analysis, BRAF mutations were signiﬁcantly correlated
with the presence of either multiple HCC nodules (P¼0.021) or higher proliferation rates (P¼0.034). Although further extensive
screenings are awaited in HCC patients among different populations, our ﬁndings clearly indicated that mutational activation of
both BRAF and PIK3CA genes does contribute to hepatocellular tumorigenesis at somatic level in Southern Italian population.
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Hepatocellular carcinoma (HCC) is among the most common
malignancies worldwide, with approximately more than
500000 new patients diagnosed each year; however,
signiﬁcant regional differences in the incidence of HCC are
observed because of the frequency of the different aetiologi-
cal factors involved in HCC development.
1
Despite major efforts to improve diagnosis and treatment of
HCC, therapeutic options remain limited; treatment options
depend on the stage of the disease and the extent of liver
dysfunction and cirrhosis.
2 Therefore, targeting the key-role
genes and pathways have increasingly gained attention.
Actually, molecular mechanisms leading to malignant trans-
formation of hepatocytes as well as development and progres-
sion of HCC still remain largely unclear. The mitogen-activated
protein kinase (MAPK) pathway (including the cascade of
RAS, BRAF, MEK1/2, and extracellular-signal-regulated kinase
(ERK)1/2 proteins) has emerged as a major signalling cascade,
involved in the control of cell growth, proliferation, and migration
in majority of the cancers. Recently, sorafenib, an oral multi-
kinase inhibitor targeting BRAF among other cellular kinases,
has been demonstrated to be effective in HCC.
3
Besides a well-documented overexpression of RAS in
human HCC,
4 activating mutations of the RAS oncogenes
(particularly those affecting the K-RAS gene) have been
classiﬁed as rare events during hepatocarcinogenesis.
5
On the other hand, RAS mutations have been frequently
identiﬁed in HCC induced by various chemical agents in
animals.
6 From the same signalling cascade, somatic muta-
tions of the BRAF serine/threonine kinase gene have been
reported at various frequencies among different types of
human cancers.
7 Similar to the RAS alterations, BRAF
mutations seem to poorly participate in the pathogenesis of
human HCC.
8 However, a clear statement about the
prevalence of both RAS and BRAF mutations in HCC is yet
to be deﬁnitely assessed, and differences may exist because
of the geographical origins of the patients’ populations and
probably to the different aetiological factors that have been
involved in hepatocellular carcinogenesis.
A higher amount of reports has been published revealing
that the phosphoinositide-3-kinase-catalytic-alpha (PIK3CA)
gene may be somatically mutated in several types of human
cancer,includingHCC.
9–10Inparticular,PIK3CAisaneffector
of the phosphatase and tensin homologue (PTEN)–AKT
pathway, which is involved in the inhibition of focal adhesion
formation, cell spreading, and migration, as well as in the
inhibition of growth factor-stimulated MAPK signalling (altera-
tions in the RAS–BRAF pathway are frequently associated
with the PTEN–PIK3CA impairments).
11
In the present study, we analysed the mutational status of the
K-RAS, BRAF, and PIK3CA genes in a series of HCC tissues
from patients originating from South Italy, to further elucidate the
possible role of these genes in primary hepatic malignancies.
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Genomic DNA from 65 consecutively collected HCC patients
was screened for somatic mutations in BRAF, K-RAS, and
PIK3CA genes. The study population consisted of 48 (74%)
males and 17 (26%) females, with a median age of 69
years (range, 58–81 years). Histological patterns included
trabecular (41 cases; 63%), solid (21; 32%), mixed (1; 2%),
and unclassiﬁed (2; 3%) types.
The full coding sequence and intron–exon junctions of the
candidate exons (see Materials and Methods) were assessed
in such different HCC samples. Figure 1 shows the nucleotide
sequences for the somatic mutations identiﬁed in our series.
Overall, mutations were detected in 15 (23%) HCCs for the
BRAF gene, 18 (28%) cases for the PIK3CA gene, and 1 (2%)
patient for the K-RAS gene (the rates of each speciﬁc
mutation are shown at bottom of Figure 1). Four cases
presented co-existence of BRAF and PIK3CA mutations;
altogether, 30/65 (46%) patients carried a somatic mutation in
at least one of the above-mentioned genes. All BRAF
mutationswere represented bythe most commonsubstitution
of valine by glutamic acid at position 600 (V600E; Figure 1).
None of the sequence changes identiﬁed was present in
normal adjacent tissues from the same HCC cases, indicating
that these variants are tumour-speciﬁc and somatically
acquired mutations.
Using statistical tests, BRAF and PIK3CA mutations were
evaluated for association with several pathological para-
meters: sex, age at diagnosis, tumour grading, pathological
tumour size (pT; according to the TNM classiﬁcation
13), total
number of tumour lesions within hepatic parenchyma (single
or multiple HCC nodules), and rate of proliferations (as
inferredbythelevelsoftumourmitosis;Table1).Inourseries,
the only signiﬁcant correlation was found between the
occurrence of BRAF mutations and the presence of either
multiple HCC nodules (P¼0.021) or higher proliferation rates
(P¼0.034; Table 1). No signiﬁcant association was observed
between the BRAF or PIK3CA mutations and other para-
meters (though a trend for BRAF mutations to be associated
withanolder ageof onset,a higher tumourgrade, anda larger
Figure 1 Sequencing results for identiﬁed somatic mutations. Electropherograms show the nucleotide sequences of the genomic DNA from positive HCC samples;
arrows indicate the mutation position within the sequence. Bottom right: prevalence of all mutations, designed for both DNA and amino acid changes
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conversely associated with earlier primary HCC was inferred;
Table 1).
Discussion
In this study, we examined the frequency of activating
mutations of the BRAF, K-RAS, and PIK3CA genes in a
series of 65 human HCC samples from patients originating
from South Italy. In our series, K-RAS mutations were quite
absent (only one patient presented an oncogenic mutation in
this gene) conﬁrming data from literature, indicating that
mutations in K-RAS are rare and likely not a key event in
hepatocarcinogenesis. On the other hand, a higher-than-
expected prevalence of somatic mutations was observed for
the BRAF gene (15/65; 23%). In the unique previous study on
this issue, no BRAF mutation was indeed observed in a small
subset of human HCC patients.
8 One could speculate that the
higher frequency detected in our series may be somehow due
to the patients’ origin or, in other words, to the different
‘genetic background’ of populations from the two studies.
Moreover, it cannot be excluded that different aetiological
factors could be involved in the HCC development among
different populations, and therefore, different mechanisms of
transformation could occur. The most common mutation in
BRAF gene (nearly, 90% of cases) is a substitution of valine
with glutamic acid at position 600 (V600E).
7 This mutation,
which is present in exon 15 within the kinase domain,
represented the only variant identiﬁed in our HCC tissues.
Controversial data have been published about the PIK3CA
mutation rates, ranging from none
14 to one-third
9–10 of the
HCC cases presenting a mutated PIK3CA (interestingly, the
two main contrasting reports are based on patients from the
Eastern populations). In the present study, mutations
were detected in quite a high fraction of the HCC tissues
(18/65; 28%).
Overall, our study provides clear indications that mutational
activation of both the BRAF and PIK3CA genes indeed
participates to hepatocellular tumorigenesis at the somatic
level in the southern Italian population. From the functional
point of view, BRAF and RAS are members of the MAPK
(RAS–BRAF–MEK–ERK) pathway, which mediates cellular
response to growth signals. In particular, activated BRAF or
RAS (mutation in encoding two genes have been demon-
strated to be mutually exclusive
15–16) participate in the
sustained induction of cell cycle progression. More in general,
the MAPK and the PIK3CA signalling pathways both have a
key role in cell proliferation and survival; their oncogenic
activation deeply contributes to pathogenesis of different solid
tumours, including HCC.
Nevertheless, BRAF and PIK3CA mutations were more or
less equally distributed among the different patients’ subsets
in our series, and no statistically signiﬁcant correlation with
sex, onset age, histological tumour type, primary tumour size,
and grading were observed. However, patients with HCC
carrying a mutated BRAF are more likely to signiﬁcantly
present with multifocal or more aggressive disease (see
Table 1).
More extensive screenings should be carried out to conﬁrm
the prevalence and distribution of BRAF- and PIK3CA-
activating mutations in HCC among different populations.
Actually, this need is particularly strong, as inhibition of the
RAS–BRAF–MEK–ERK pathway may be an important new
therapeutic strategy in HCC. More speciﬁcally, BRAF muta-
tions have become a favoured target for the treatment of
advanced HCC, because of the clinical development of the
RAF-kinase inhibitor sorafenib that has found indication in the
treatment of HCC in the United States, Europe, and Asia.
17–18
The different response rates observed in the clinical trials that
led to the registration of sorafenib in HCC treatment could be,
on the basis of our data, not only due to the different status of
accompanying cirrhotic disease, but also to a different
distribution of candidate gene mutations. Therefore, it should
be interesting to correlate such a mutational status to the
clinical responsiveness. In this view, we have recently
demonstrated that the decrease of the phosphorylation of
downstream ERK (a surrogate marker of the RAF kinase
activity) is a predictive marker of response to a combination
between sorafenib and octreotide in advanced HCC.
19–20
Trying to point out such issues, we already started a new
study in which HCC patients are being prospectively enrolled
and adequately followed-up, with registration of all the main
clinical information (type of treatment(s), clinical behaviour of
the disease, date of last control or death) and inclusion of the
expression analysis by immunohistochemistry for several
effectors of the BRAF–PI3K pathways (K-RAS, MEK,
phospoERK, PTEN, AKT).
Finally, our ﬁndings may provide new therapeutic options
for the subset of patients carrying the
V600EBRAF mutations,
Table 1 Distribution of mutations according to the characteristics of HCC
patients
BRAF PIK3CA
Characteristics
(patients)
Mutated
cases
% P Mutated
cases
% P
Sex
Male (N¼48) 11 23 0.972 13 27 0.875 Female (N¼17) 4 24 5 29
Age
r60 (N¼13) 2 15 0.219 43 1 0.822 460 (N¼52) 13 25 14 27
Grading
G2 (N¼52) 11 21 0.211 15 29 0.427 G3 (N¼13) 4 31 3 23
pT
pT1 (N¼20) 4 20 8 40
pT2 (N¼34) 7 21 0.187 8 24 0.106
pT3 (N¼11) 4 36 2 18
No. of tumour sites
Single (N¼43) 4 9 0.021 13 30 0.353 Multiple (N¼22) 11 50 5 23
No. of tumour mitoses
Low (N¼47) 6 13 0.034 14 30 0.321 High (N¼18) 9 50 4 22
Abbreviations: HCC, hepatocellular carcinoma; PIK3CA, phosphoinositide-3-
kinase-catalytic-alpha
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developed.
21–23 Vemurafenib, a speciﬁc inhibitor of the
BRAF
V600E variant, has indeed showed a very promising
activity in patients positive for such a mutation.
23 Never-
theless, the identiﬁcation of a mutated PIK3CA gene, which is
becoming a promising target for newly discovered anticancer
drugs,
24 potentially gives an additional opportunity for
identifying HCC patients who may beneﬁt from alternative
treatment strategies. One could hypothesize that new
therapies, aimed at blocking the key molecular pathways,
which are differently altered during hepatocellular tumori-
genesis, in combination with the molecular classiﬁcation of
such distinct patients’ subsets may become the gold standard
for future treatment approaches in the HCC disease.
Materials and Methods
Samples. A total of 65 patientswith histologically proven diagnosis of HCC were
included into the study. For tumour typing, the classiﬁcation according the AJCC/
UICC guidelines was adopted.
12 Tumour size was based on the largest dimension
of the tumour specimen. Multiple lesions were deﬁned by the presence of two or
more nodules of tumours including intrahepatic metastasis.
Neoplastic tissue samples were obtained from pathological archives using
appropriate informed consent procedures. The study was reviewed and approved
by the ethical review board of the University of Sassari.
Mutation analysis. For mutation analysis, genomic DNA was isolated from
tumour tissue samples, using standard methods. Tumour tissues were estimated to
contain at least 70% neoplastic cells by light microscopy.
The complete coding sequences and intron–exon boundaries of the K-RAS
exons 2–3, BRAF exon 15, and PIK3CA exons 9–20, were screened for mutations
by direct sequencing, using an automated ﬂuorescence-based cycle sequencer
(ABIPRISM3100, Applied Biosystems, Foster City, CA, USA). Primer sequences
were as reported in Genome DataBase (http://www.gdb.org).
Statistical analysis. Fisher’s exact test and w
2-test were used to evaluate
possible associations between covariates (mutated and wild-type genotypes) and
clinical or pathological parameters. Variables were also evaluated for independent
correlations by Cox regression analysis. Statistical comparisons were performed
using the SPSS statistical software package, version 15.0 (SPSS Inc., Chicago, IL,
USA).Alltestsweretwo-tailedandP-valuesoflessthan0.05wereconsideredtobe
statistically signiﬁcant.
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